Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

BACKGROUND: Treatment with direct-acting antiviral agents (DAAs) offers an opportunity to eliminate hepatitis C virus (HCV) endemic among people who inject drugs (PWID) and people enrolled in opioid agonist therapy (OAT) programs. The objective of this study was to estimate and to compare HCV treatm...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Subst Abuse Treat Prev Policy
Autori principali: Aas, Christer F., Vold, Jørn Henrik, Skurtveit, Svetlana, Odsbu, Ingvild, Chalabianloo, Fatemeh, Lim, Aaron G., Johansson, Kjell Arne, Fadnes, Lars Thore
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7325258/
https://ncbi.nlm.nih.gov/pubmed/32605625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13011-020-00286-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi